Medical technology company Becton, Dickinson and Company (NYSE: BDX) announced better-than-expected revenue in Q4 CY2025, with sales up 1.6% year on year to $5.25 billion. Its non-GAAP profit of $2.91 per share was 3.5% above analysts’ consensus estimates.
Is now the time to buy BDX? Find out in our full research report (it’s free for active Edge members).
BD (BDX) Q4 CY2025 Highlights:
- Revenue: $5.25 billion vs analyst estimates of $5.15 billion (1.6% year-on-year growth, 2.1% beat)
- Adjusted EPS: $2.91 vs analyst estimates of $2.81 (3.5% beat)
- Adjusted EBITDA: $1.35 billion vs analyst estimates of $1.30 billion (25.7% margin, 3.7% beat)
- Management lowered its full-year Adjusted EPS guidance to $12.50 at the midpoint, a 16.1% decrease
- Operating Margin: 10.5%, up from 8.8% in the same quarter last year
- Constant Currency Revenue was flat year on year (9.6% in the same quarter last year)
- Market Capitalization: $59.09 billion
StockStory’s Take
Becton, Dickinson and Company’s fourth quarter results were shaped by ongoing portfolio transformation, targeted investments in growth platforms, and the headwind of international tariffs. Management credited strong performance in biologic drug delivery, advanced tissue regeneration, and pharmacy automation, with CEO Thomas E. Polen highlighting "broad-based growth across the markets where we have been doubling down on investments." However, persistent challenges in China and vaccine-related pressures tempered overall top-line momentum, while productivity initiatives and operational discipline supported margin improvement.
Looking forward, BD’s revised outlook is influenced by a sharpened focus on high-growth, high-margin areas such as connected care, advanced patient monitoring, and tissue regeneration, alongside continued commercial and R&D investments. Management remains cautious about persistent macroeconomic and regulatory headwinds, especially from China and vaccine demand, but expects recent product launches and a simplified manufacturing network to support margin stability. CFO Vitor Roach emphasized, "We are maintaining a prudent approach to our guidance for new BD," citing ongoing portfolio shifts and targeted capital allocation.
Key Insights from Management’s Remarks
Management attributed the quarter’s results to accelerated commercial efforts in prioritized segments, ongoing portfolio divestitures, and disciplined productivity initiatives.
- Growth in prioritized platforms: Double-digit gains in biologic drug delivery, advanced tissue regeneration, and PureWick home care products drove most of the quarter’s growth, supported by expanded sales force investments and commercial wins.
- Portfolio transformation completed: The closure of the Waters life sciences transaction marked BD’s further shift towards a pure-play medtech model, with $4 billion in proceeds allocated equally to share repurchases and debt reduction.
- Operational improvements: Network consolidation reduced manufacturing sites by nearly half, enabling cost efficiencies and improved resilience. Productivity initiatives delivered an 8% improvement, partially offsetting tariff impacts.
- China and vaccine headwinds: About 10% of the portfolio continued to face pressure from China’s volume-based procurement and lower vaccine demand. Management expects these challenges to persist through the year but to become less material over time.
- Innovation pipeline acceleration: Reallocation of $50 million in R&D funding led to faster product development, with notable launches in pharmacy automation, biosurgery, and wound care. Management highlighted regulatory clearances and market introductions as critical contributors to future growth.
Drivers of Future Performance
BD expects growth to be driven by continued expansion in targeted high-growth segments, operational improvements, and disciplined capital allocation, while monitoring ongoing headwinds in select markets.
- High-growth segment focus: Management is increasing commercial and R&D investments in areas like advanced patient monitoring, connected care, and biologics, which are expected to deliver above-average growth and higher gross margins relative to the broader portfolio.
- Mitigating external pressures: Tariffs and pricing challenges, especially in China, remain headwinds. BD is leveraging productivity gains, simplified manufacturing, and positive pricing trends outside China to offset these impacts.
- Capital deployment and portfolio reshaping: Proceeds from the Waters transaction are being used for share repurchases and debt reduction, with tuck-in M&A remaining a strategic priority to supplement organic growth in high-potential healthcare markets.
Catalysts in Upcoming Quarters
In the coming quarters, our analyst team will be monitoring (1) the pace of commercial adoption for new product launches such as Pyxis Pro, Avatene Flowable, and HemoSphere Stream; (2) execution of manufacturing network consolidation and resulting margin improvements; and (3) stabilization of China and vaccine-related headwinds. Progress on tuck-in acquisitions and continued innovation pipeline acceleration will also be essential signposts for sustained growth.
BD currently trades at $203, down from $210.02 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
Our Favorite Stocks Right Now
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
